Nektar Therapeutics buy Oppenheimer Holdings Inc.
Start price
14.03.25
/
50%
€0.82
Target price
14.03.26
€5.53
Performance (%)
-29.01%
Price
06.06.25
€0.58
Summary
This prediction is currently active. The prediction for Nektar Therapeutics disappoints with a performance of -29.01%. This prediction currently runs until 14.03.26. The prediction end date can be changed by Oppenheimer_Holdings at any time. Oppenheimer_Holdings has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Nektar Therapeutics | - | - |
| iShares Core DAX® | 0.191% | 4.892% |
| iShares Nasdaq 100 | -0.614% | 2.901% |
| iShares Nikkei 225® | 0.599% | 7.404% |
| iShares S&P 500 | -0.036% | 3.489% |
Comments by Oppenheimer_Holdings for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat